AGP Executive Report
Last update: 8 hours agoFDA & Biotech: Genentech’s Enspryng (satralizumab) for thyroid eye disease has been granted FDA priority review for a decision expected by Oct. 15, 2026, after Phase III SatraGO results. Regulatory Approvals: Hengrui’s Heng Yi (0.1% cyclosporine ophthalmic solution) was approved in China as an innovative dry eye disease treatment. Hospital Safety & Staffing: In Ireland, nurses and midwives plan a lunchtime protest over unsafe staffing at University Maternity Hospital Limerick, citing deficits and HIQA findings. Drug Misuse Probe: South Korea police referred 20 hospital staff over alleged repeated administration of unprescribed anti-anxiety drugs, including alleged record-keeping cover-ups. Public Health & Resistance: WHO released a blueprint to tackle fungal disease burden and antifungal resistance, urging countries to add fungal threats to health plans. Healthcare Access & Tech: Tripura will receive AI-enabled portable X-ray devices plus MRI and breast tomosynthesis systems to expand district diagnostics. Mental Health Focus: Ghana’s mental health group backs mandatory mental health and drug screening for public-sector hiring, arguing it supports safer workplaces. Workplace Violence: A Massachusetts report highlights how assaults and threats against hospital workers are driving staffing strain.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
